Dawn Svoronos

Dawn Svoronos is a declared insider at 7 companies (board member); the most frequent names are PTC Therapeutics, Inc., Global Blood Therapeutics, Inc. and Adverum Biotechnologies, Inc. We count 31 filings; the first trade dates from 14 March 2016 and the latest from 1 September 2026.

In open-market terms, that means 5 purchases worth €863k on one side and 11 sales worth €1.4M on the other. The net balance comes to €574k on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 5 share grants and 4 option exercises.

In size, the median ticket on the buying side is €171k. Clusters matter here: 4 out of 5 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster.

The newest entry dates from 3 September 2026: an option exercise of €36k, in Xenon Pharmaceuticals Inc. The last purchase on record was published on 11 May 2023, which is 1,262 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.